vTv Therapeutics, Inc. (VTVT)
33.89
+0.64
(+1.91%)
USD |
NASDAQ |
Aug 24, 16:00
33.61
-0.28
(-0.83%)
Pre-Market: 20:00
vTv Therapeutics Net Income (Quarterly) : -13.05M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -13.05M |
| March 31, 2026 | 24.13M |
| December 31, 2025 | -7.138M |
| September 30, 2025 | -10.34M |
| June 30, 2025 | -7.38M |
| March 31, 2025 | -6.217M |
| December 31, 2024 | -4.437M |
| September 30, 2024 | -5.84M |
| June 30, 2024 | -6.409M |
| March 31, 2024 | -6.019M |
| December 31, 2023 | -4.441M |
| September 30, 2023 | -8.54M |
| June 30, 2023 | -7.211M |
| March 31, 2023 | -5.774M |
| December 31, 2022 | -6.09M |
| September 30, 2022 | -5.468M |
| June 30, 2022 | -4.091M |
| March 31, 2022 | -9.424M |
| December 31, 2021 | -9.483M |
| September 30, 2021 | -1.465M |
| June 30, 2021 | -0.841M |
| March 31, 2021 | -5.942M |
| December 31, 2020 | 1.607M |
| Date | Value |
|---|---|
| September 30, 2020 | -2.253M |
| June 30, 2020 | -4.991M |
| March 31, 2020 | -7.165M |
| December 31, 2019 | -7.516M |
| September 30, 2019 | -6.467M |
| June 30, 2019 | -5.114M |
| March 31, 2019 | -7.71M |
| December 31, 2018 | -3.067M |
| September 30, 2018 | -1.961M |
| June 30, 2018 | -9.596M |
| March 31, 2018 | -9.96M |
| December 31, 2017 | -14.59M |
| September 30, 2017 | -12.36M |
| June 30, 2017 | -13.41M |
| March 31, 2017 | -14.29M |
| December 31, 2016 | -13.71M |
| September 30, 2016 | -13.50M |
| June 30, 2016 | -14.62M |
| March 31, 2016 | -13.52M |
| December 31, 2015 | -11.06M |
| September 30, 2015 | -9.822M |
| June 30, 2015 | -32.90M |
| March 31, 2015 | -9.713M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Spyre Therapeutics, Inc. | -36.20M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 13.05M |
| EPS Diluted (Quarterly) | -1.052 |
| Enterprise Value | 46.84M |
| Earnings Yield | -3.12% |
| Normalized Earnings Yield | -3.127 |